The purpose of this study is to compare the usual treatment of immune therapy alone to using radiation therapy plus the usual treatment.
Learn more about the NRG-GU012 trial or call the Reading Hospital Cancer Research Office at 484-628-8193.
NRG-GU012
Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)
